Distribution can shape sildenafil duration by controlling how drug moves between plasma and tissues after systemic absorption. The concept of duration distribution focuses on tissue uptake, redistribution, distribution volume, and distribution rate as determinants of exposure persistence. The duration definition establishes the interval over which an effect is considered to persist, while pkpd overview connects distribution to the concentration-effect relationship. The onset distribution phase provides a framework for understanding early movement from plasma into tissues, while onset plasma levels describe the circulating concentration trajectory. The onset cmax relation places peak exposure within that trajectory. Metabolic handling also interacts with distribution, as described by onset metabolism impact and onset cyp3a4. Together these processes shape the effect window. After time to effect and threshold crossing, redistribution and elimination can influence how quickly exposure declines. Distribution-driven duration differs from duration long and duration short, while variability factors and timing consistency describe individual differences.
Distribution does not simply mean movement away from plasma. It is a dynamic process involving transfer between compartments, tissue uptake, release from tissues, and the changing relationship between plasma concentration and concentrations at potential effect sites. Distribution volume provides a conceptual measure of how extensively drug appears to occupy physiological compartments relative to plasma, while distribution rate describes how quickly that movement occurs. Tissue affinity can influence how strongly sildenafil partitions into particular compartments and how long it remains associated with them. These factors can alter plasma decline without necessarily representing irreversible elimination. A rapid early plasma decrease can reflect distribution into tissues, whereas later redistribution can contribute to continued systemic exposure. The duration consequence depends on whether the tissues receiving drug act as transient reservoirs and whether concentrations within relevant compartments remain sufficient to support a pharmacodynamic response. Metabolism and elimination continue during this process, so distribution and clearance are coupled rather than sequentially isolated events. A distribution-driven duration pattern therefore emerges from the balance between tissue uptake, redistribution, metabolic removal, and the concentration-effect relationship.
Distribution can affect duration without determining it independently. Absorption establishes the amount and timing of sildenafil entering systemic circulation, while gastric emptying and food effects can shift that initial input. Once drug reaches plasma, distribution determines how quickly it moves into tissues and how extensively it occupies peripheral compartments. Age, BMI, health conditions, dosing conditions, drug interactions, alcohol, and smoking can influence one or more of these processes and therefore contribute to variability in distribution-driven duration. A larger apparent distribution volume can lower measured plasma concentration relative to the administered systemic amount, while a smaller volume can leave a greater proportion of exposure within the circulating compartment. Neither characteristic alone establishes a longer or shorter effect window because pharmacodynamic response depends on concentrations within relevant compartments. Distribution-driven duration is therefore best understood as an exposure-persistence mechanism. It can contribute to a duration long pattern when tissue persistence and redistribution sustain relevant exposure, or to a duration short pattern when distribution does not maintain relevant concentrations and clearance reduces exposure comparatively early.
Distribution-driven duration begins with the movement of sildenafil between the circulating plasma compartment and tissues. The duration distribution framework focuses on how tissue uptake, redistribution, distribution volume, and distribution rate affect exposure persistence. The duration definition specifies the time interval being measured, while the onset distribution phase describes the early movement of drug away from plasma. As distribution proceeds, onset plasma levels can decline even when the total amount of drug in the body has not decreased proportionally, because drug is being redistributed among compartments. The onset cmax relation places peak plasma exposure within this broader concentration-time trajectory. Distribution can therefore create an apparent plasma decline that reflects compartmental movement rather than immediate elimination. If tissue concentrations persist and subsequently return drug to plasma, redistribution can prolong systemic exposure. If tissue uptake is limited or clearance dominates, relevant exposure may decline sooner. The resulting pattern contributes to the effect window.
Distribution volume describes the apparent extent to which sildenafil occupies physiological compartments relative to the measured plasma concentration. A larger apparent distribution volume generally indicates greater partitioning outside the plasma compartment, although it does not by itself specify how long drug remains in any particular tissue. Distribution rate describes the speed of movement between compartments, while tissue affinity can influence the extent and persistence of uptake. These characteristics affect the shape of the concentration-time curve and can modify the relationship between plasma concentration and exposure at a potential effect site. A rapid distribution process may produce an early plasma decline, whereas slower redistribution may create a more extended tail in the overall exposure profile. Metabolism occurs concurrently and can remove parent drug before redistributed drug returns to plasma. Consequently, the duration effect of distribution depends on the balance between tissue uptake, release, metabolic clearance, and pharmacodynamic response. Distribution should therefore be interpreted as a dynamic determinant of persistence rather than as a simple storage process. The resulting exposure pattern can support either earlier or later effect offset depending on the underlying compartmental behavior.
The relationship between distribution and duration is especially important when distinguishing plasma exposure from effect-site exposure. Plasma concentration is an accessible marker, but the concentration associated with pharmacodynamic response may reflect distribution into tissues or other compartments. A response can therefore persist while plasma concentration declines if relevant exposure remains available outside the central compartment. Conversely, a substantial plasma concentration does not automatically imply prolonged effect if the effect-linked compartment is not maintained at comparable exposure. This distinction connects distribution with the effect window and the selected duration definition. It also explains why a distribution-driven profile can differ from one dominated by metabolic clearance. Metabolism removes parent drug through biotransformation, whereas distribution primarily redistributes unchanged drug between compartments. Both processes can reduce plasma concentration, but their implications for persistence differ. A distribution-dominant profile may show redistribution or tissue persistence after an early plasma decline. A clearance-dominant profile may show continuing exposure reduction without substantial compartmental return. Duration is therefore the integrated result of these processes and their relationship to pharmacodynamic response.
Distribution begins only after sildenafil becomes available systemically, so the initial absorption profile establishes the amount and timing of drug presented to the distribution compartments. onset food impact describes how food can modify oral input, while onset fatty food delay addresses delayed absorption associated with a fatty meal. onset gastric emptying is relevant because gastrointestinal transit influences when sildenafil reaches the principal absorptive region. The onset absorption phase therefore establishes the initial systemic exposure from which distribution proceeds. onset plasma levels then reflect the combined effects of input and movement between compartments. A delayed input profile can shift the timing of distribution without necessarily changing the intrinsic distribution rate or tissue affinity. Conversely, rapid absorption can expose tissues earlier without automatically producing longer persistence. Distribution-driven duration must therefore distinguish the timing of systemic entry from the later processes that determine tissue uptake, redistribution, and release. Food-related timing changes are important because they can reposition the entire exposure trajectory relative to the duration clock.
Food effects and gastric emptying can indirectly influence distribution-driven duration by determining when and how much sildenafil reaches systemic circulation. A fatty meal may delay absorption, causing the distribution phase to begin later relative to administration. This can shift apparent onset and peak timing even if the underlying tissue distribution characteristics remain unchanged. Gastric emptying similarly controls the timing of gastrointestinal delivery and therefore the availability of drug for absorption. Once systemic concentrations rise, distribution volume and tissue affinity determine how the available drug partitions between plasma and peripheral compartments. The concentration entering those compartments depends on the preceding absorption trajectory, so input and distribution are mechanistically connected. However, a delayed input should not automatically be interpreted as enhanced tissue persistence. Likewise, a higher systemic exposure does not necessarily mean that the distribution phase will be proportionally longer. Duration emerges from the combined timing of absorption, distribution, redistribution, metabolism, and pharmacodynamic response. The distinction is particularly useful when interpreting why two profiles can have different onset times but similar distribution-driven persistence, or similar onset times but different later plasma decline.
Distribution can also modify the relationship between peak concentration and later exposure persistence. If a substantial fraction of systemic drug rapidly enters peripheral compartments, plasma concentration can decline after peak even while tissue exposure is increasing. Later redistribution can return some drug to plasma and produce a prolonged concentration tail. Metabolism can occur throughout this process, reducing the amount available for redistribution. Thus, food, gastric emptying, and absorption determine the timing of the initial input, while distribution determines how that input is partitioned across compartments. The resulting effect window depends on which compartment most closely tracks pharmacodynamic response. An apparent delay in plasma exposure can therefore arise from gastrointestinal timing, whereas a later decline can reflect distribution or metabolic processes. These mechanisms should be kept conceptually separate even though they operate on the same concentration-time curve. Distribution-driven duration is consequently best interpreted by following the complete trajectory from absorption through plasma exposure, tissue uptake, redistribution, and clearance rather than assigning duration to a single input variable.
| Distribution Determinant | PK Basis | Timing Impact |
|---|---|---|
| Food effects | Food can modify the timing and extent of systemic sildenafil input before distribution begins. | Can shift when distribution starts without necessarily changing intrinsic tissue kinetics. |
| Fatty meals | A fatty meal can delay oral absorption and alter the early concentration-time profile. | May delay apparent onset and redistribute the timing of subsequent exposure milestones. |
| Gastric emptying | Gastric transit affects delivery of sildenafil to the intestinal absorption region. | Changes when systemic drug becomes available for tissue distribution. |
| Absorption phase | The rate and extent of systemic input determine the concentration presented to distribution compartments. | Sets the initial timing and magnitude of tissue uptake. |
| Plasma levels | Plasma concentration reflects input, distribution, redistribution, metabolism, and elimination. | Provides a time-dependent marker of compartmental movement and exposure persistence. |
The early PK/PD trajectory provides the foundation for understanding how distribution later contributes to duration. onset plasma levels describe the circulating concentration as systemic input begins, while onset cmax relation places peak exposure within the overall profile. The onset distribution phase then describes movement between plasma and peripheral compartments. This movement can produce an early plasma decline even before metabolic clearance becomes the dominant determinant of concentration. onset metabolism impact and onset cyp3a4 provide the complementary metabolic perspective: CYP3A4-mediated transformation removes parent sildenafil while distribution changes where unchanged drug is located. The two processes can operate simultaneously and shape different portions of the concentration-time curve. The timing of effect establishment is conceptually represented by time to effect, but later offset depends on how long relevant concentrations persist within the compartment associated with the pharmacodynamic response. Distribution can therefore alter the interval between threshold entry and subsequent decline without being equivalent to elimination.
Distribution volume and tissue affinity help determine how sildenafil is partitioned after entering systemic circulation. A greater apparent distribution volume can be associated with lower plasma concentrations relative to the total amount present because more drug occupies peripheral compartments. Distribution rate determines how quickly this partitioning occurs, while tissue affinity can influence how readily drug associates with particular compartments. These characteristics can alter the timing of plasma decline and redistribution. However, the pharmacodynamic response depends on exposure at the relevant effect site, not simply on the total amount distributed. A rapidly declining plasma concentration may therefore coexist with sustained effect if relevant tissue exposure persists. Conversely, extensive distribution does not automatically imply a prolonged effect because metabolism and elimination can remove parent drug from the system while tissue uptake and release continue. The resulting duration reflects a balance among compartmental movement, clearance, and concentration-effect sensitivity. This is why distribution should be treated as a mechanistic contributor to duration rather than a direct proxy for effect length.
Threshold crossing connects the distribution trajectory to the duration interval. During the rising phase, systemic exposure approaches the concentration region associated with a relevant response. During the later phase, declining plasma and tissue exposure can move the system away from that region. Distribution can delay or extend this second transition if tissue compartments retain relevant drug and subsequently redistribute it. Conversely, rapid redistribution followed by efficient metabolic clearance can shorten persistence. time to effect describes the early timing transition, while duration concerns the interval through subsequent exposure and response. The relationship is therefore not simply a matter of when plasma concentration falls. It depends on which compartment is pharmacodynamically relevant and how quickly exposure within that compartment changes. Metabolism can shorten persistence by transforming parent drug, while distribution can either buffer or accentuate plasma decline depending on compartmental kinetics. The PK/PD interpretation must consequently integrate plasma concentration, tissue exposure, redistribution, metabolism, and the concentration-effect relationship before assigning a mechanistic explanation to duration.
Distribution-driven duration should be separated from onset speed because distribution can influence both the early rise and the later persistence of exposure. onset fast describes rapid establishment of relevant exposure, while onset slow describes delayed establishment. Either can coexist with substantial or limited distribution persistence. The framework in onset vs duration basics separates the rising onset interval from the later duration interval, while onset vs duration graph illustrates these phases on a common time axis. The duration definition determines which onset and offset reference points are used. A rapid distribution phase can produce an early plasma decline after peak, but that decline may not equal loss of effect if tissue exposure remains relevant. Conversely, slow distribution can delay the appearance of some tissue exposure while potentially creating a prolonged redistribution phase. Thus, onset speed and distribution-driven duration are related but distinct. Duration depends on the complete compartmental trajectory rather than the steepness of the initial rise alone.
A graph can reveal distribution-driven duration through differences between plasma decline and the persistence of the broader exposure or response trajectory. A profile with rapid tissue uptake may show an early fall in plasma concentration after peak, followed by a slower terminal component associated with redistribution and elimination. Another profile may show limited peripheral uptake and a more direct relationship between plasma decline and declining response. The visual distinction becomes important when interpreting apparent short or long duration. A rapid plasma decline does not necessarily mean duration short if tissue exposure persists, while extensive tissue distribution does not automatically create duration long if metabolic clearance rapidly removes parent drug. The onset vs duration graph can therefore be interpreted as a combination of compartmental movement and concentration-effect behavior. Distribution-driven duration is most apparent when the post-peak trajectory shows evidence of compartmental persistence or redistribution that changes the timing of exposure decline relative to plasma concentration alone.
The separation between onset and duration is especially useful when distribution changes without a comparable change in absorption. A change in distribution rate can alter how quickly plasma concentration falls after systemic input while leaving the initial absorption process largely intact. A change in tissue affinity can modify how much drug remains in peripheral compartments and how readily it returns to plasma. These changes can affect the later exposure tail without necessarily producing the same directional change in onset. Conversely, food or gastric emptying can shift onset timing while distribution kinetics remain relatively stable. onset vs duration basics therefore provides a framework for keeping input timing separate from compartmental persistence. The duration definition determines where the later interval begins and ends. Graph interpretation then depends on identifying the rising phase, distribution-related decline, redistribution behavior, and eventual exposure reduction. Distribution-driven duration is consequently defined by how compartmental movement shapes persistence, not by whether onset is simply fast or slow.
| Timing Component | PK/PD Basis | Interpretation |
|---|---|---|
| Fast onset | Rapid absorption and early systemic exposure establish relevant concentrations quickly. | Can coexist with either limited or prolonged distribution persistence. |
| Slow onset | Delayed input or slower early distribution postpones relevant exposure. | Does not by itself determine how long tissue exposure persists. |
| Distribution phase | Drug moves from plasma into peripheral compartments at a characteristic rate. | Can produce early plasma decline while tissue exposure continues to develop. |
| Redistribution | Drug returns between compartments after earlier tissue uptake. | Can prolong the exposure tail or alter the timing of effect decline. |
| Onset-duration separation | Rising exposure and later compartmental persistence reflect different temporal processes. | Allows distribution-driven duration to be distinguished from onset speed. |
Distribution-driven duration varies because tissue uptake and compartmental movement depend on physiological and exposure-related characteristics. variability factors can alter absorption, distribution volume, tissue affinity, blood flow, metabolic clearance, and pharmacodynamic sensitivity. timing consistency concerns how reproducibly these processes generate similar exposure and response trajectories under comparable conditions. Age-related physiological changes provide context for onset age impact, while body composition can influence distribution characteristics considered through onset bmi impact. Health conditions can affect gastrointestinal function, circulation, hepatic processing, tissue perfusion, or other determinants of distribution, as represented by onset health conditions. Drug interactions may alter metabolic clearance and thereby change the amount of parent drug available for redistribution, making onset drug interactions relevant to distribution-driven duration. These variables do not independently define tissue persistence. Instead, they alter the conditions under which sildenafil moves among compartments and is simultaneously metabolized and eliminated.
Alcohol and smoking can contribute to variability by changing physiological or metabolic conditions that interact with systemic drug exposure. onset alcohol provides a framework for alcohol-related timing influences, while onset smoking addresses smoking-related physiological or metabolic context. Dosing conditions also affect the amount of sildenafil entering systemic circulation and therefore the exposure presented to distribution compartments. onset dosing can consequently be considered part of the initial exposure context rather than as a direct measure of distribution kinetics. Food and gastric emptying can similarly alter when drug reaches plasma, shifting the timing of tissue uptake. Metabolic activity, including CYP3A4-mediated clearance, can then reduce the amount of parent drug available for redistribution. These interactions mean that apparent distribution-driven duration may differ even when one individual distribution parameter is unchanged. A complete interpretation therefore considers input, plasma exposure, tissue partitioning, redistribution, metabolic clearance, and pharmacodynamic response as interconnected processes rather than isolated determinants.
Clinical timing provides a descriptive framework for understanding these differences along the time axis. clinical timing concerns when exposure and response-related events occur, while timing consistency concerns how reproducibly they occur under comparable conditions. Distribution-driven variability may appear as differences in the rate of plasma decline, the duration of tissue exposure, the timing of redistribution, or the separation between plasma and effect-site concentration. A profile with greater tissue persistence may contribute to a duration long pattern, whereas limited tissue persistence combined with clearance may contribute to a duration short pattern. These outcomes cannot be assigned from distribution alone because metabolism and pharmacodynamic sensitivity also contribute. Age, BMI, health conditions, drug interactions, alcohol, smoking, and dosing can modify the surrounding PK/PD system. Distribution-driven duration is therefore best described as an integrated outcome in which compartmental movement changes exposure persistence and interacts with clearance to determine the timing of effect decline.
Distribution describes the movement of sildenafil between the circulating plasma compartment and other physiological compartments after systemic absorption. It includes tissue uptake, movement between compartments, and redistribution back toward plasma. Distribution volume describes the apparent extent of drug partitioning outside plasma relative to the measured concentration, while distribution rate describes how quickly this movement occurs. Tissue affinity can influence how strongly drug associates with particular compartments. Distribution is different from metabolism because it primarily changes where unchanged drug is located, whereas metabolism transforms parent drug into metabolites. It is also different from elimination, although all three processes can influence plasma concentration over time. Because distribution changes both plasma and tissue exposure, it can affect the timing and persistence of pharmacodynamic effects. The overall consequence depends on compartmental kinetics, clearance, and the concentration-effect relationship.
Distribution can drive duration by determining how much sildenafil moves into tissues, how quickly that movement occurs, and how long drug remains available within peripheral compartments. If tissues retain relevant amounts of drug and later redistribute it, exposure can persist beyond the initial plasma peak. This can extend the interval during which concentrations remain associated with a pharmacodynamic response. Conversely, limited tissue uptake or rapid redistribution followed by efficient clearance can contribute to earlier exposure decline. Distribution does not act alone because absorption determines the initial systemic input and metabolism removes parent drug while distribution is occurring. The effect window therefore reflects the combined behavior of plasma and tissue exposure. A distribution-driven duration interpretation focuses specifically on how compartmental movement changes persistence. It does not imply that distribution alone establishes a fixed duration or that a larger distribution volume automatically produces a longer effect.
Tissue uptake is the movement of sildenafil from the circulating plasma compartment into peripheral tissues or other physiological compartments. The extent and rate of uptake depend on distribution characteristics such as tissue affinity, blood flow, permeability, and the physicochemical relationship between drug and tissue. Tissue uptake can reduce measured plasma concentration because drug is temporarily leaving the central compartment. However, this reduction does not necessarily represent elimination because the drug may later redistribute back into plasma. If a tissue compartment retains relevant exposure, it can contribute to a prolonged concentration tail or sustained effect-site exposure. If uptake is limited, plasma concentration may track systemic exposure more directly. Tissue uptake therefore helps explain why plasma decline and effect decline are not always simultaneous. Its contribution to duration must be considered alongside redistribution, metabolic clearance, and the pharmacodynamic relationship between concentration and response.
Redistribution describes movement of drug between compartments after an earlier distribution process has occurred. Sildenafil that entered peripheral tissues can potentially move back toward plasma as concentration gradients and compartmental equilibria change. This process can create a later exposure tail even after the initial plasma concentration has fallen substantially. Redistribution can therefore influence the apparent persistence of systemic exposure and the timing of pharmacodynamic decline. However, redistributed parent drug remains subject to metabolism and elimination, so the magnitude and duration of any redistribution effect depend on the balance between tissue release and clearance. A rapid redistribution process may have little lasting effect if clearance is also rapid. More persistent tissue retention can produce a longer compartmental contribution. Redistribution is therefore a kinetic mechanism rather than a direct synonym for prolonged effect. Its significance depends on which compartment is relevant to response and how long meaningful exposure remains available.
Plasma levels provide an observable concentration-time representation of sildenafil in the circulating compartment, but they do not always represent the complete exposure history of tissues. After systemic absorption, plasma concentration can decline because drug distributes into peripheral compartments, undergoes metabolism, or is otherwise eliminated. A distribution-related plasma decline may therefore occur without an equivalent reduction in total body drug. If tissue exposure remains relevant, the pharmacodynamic effect may persist even while plasma concentration decreases. Later redistribution can return some drug to plasma and influence the shape of the concentration-time tail. For this reason, plasma levels are useful markers but should not automatically be treated as direct measurements of effect-site concentration. Duration depends on the relationship among plasma exposure, tissue exposure, metabolic clearance, and pharmacodynamic sensitivity. Distribution-driven duration specifically emphasizes how compartmental movement modifies the persistence represented by plasma measurements.
Threshold crossing is a conceptual way to describe when exposure enters or leaves a concentration region associated with a relevant pharmacodynamic response. Distribution can influence both sides of this process because movement into tissues can alter the plasma concentration available during onset, while tissue persistence and redistribution can influence the later decline. During the rising phase, rapid distribution may change the relationship between plasma and effect-site exposure. During the falling phase, retained tissue drug can delay the point at which relevant exposure falls below the response-associated region. Conversely, limited tissue persistence can allow exposure to decline more directly with plasma concentration. Threshold crossing therefore depends on compartmental behavior rather than on plasma concentration alone. The duration interval is determined by the time between the relevant entry and exit points under the selected definition. Distribution modifies the trajectory connecting those points but does not establish a universal threshold by itself.
Distribution-driven duration focuses on the contribution of tissue uptake, distribution rate, distribution volume, and redistribution to exposure persistence. A longer duration can occur when tissue compartments retain relevant drug and redistribution sustains exposure, but long duration can also arise from slower metabolic clearance or other mechanisms. A shorter duration can occur when tissue persistence is limited and plasma exposure declines quickly, but short duration can likewise result from rapid metabolic clearance. Therefore, long and short duration are broader descriptive patterns, whereas distribution-driven duration identifies one mechanistic contributor. Distribution volume alone does not determine duration because it describes apparent partitioning rather than the complete time course of tissue retention and release. The key question is how compartmental movement affects the concentration available to the pharmacodynamic system over time. Duration ultimately reflects the interaction of distribution, absorption, metabolism, elimination, and concentration-effect relationships.
The key PK concepts are absorption, distribution, metabolism, elimination, concentration-time behavior, and compartmental exposure. Distribution describes where sildenafil moves after entering systemic circulation, while pharmacodynamics describes how exposure relates to biological response. A plasma concentration can decline because drug enters tissues even before substantial metabolic elimination occurs. If those tissues retain relevant exposure, the response can persist despite a lower plasma concentration. Later redistribution can modify the exposure tail, while metabolism removes parent drug and progressively limits the amount available for redistribution. The resulting effect window depends on the concentration at the compartment relevant to response and the sensitivity of the concentration-effect relationship. Distribution-driven duration therefore emerges from the interaction of compartmental kinetics and pharmacodynamic persistence. No single parameter, such as distribution volume or peak concentration, can define the complete duration profile because the timing and magnitude of all major PK processes contribute.
Distribution-driven variability can arise from differences in body composition, tissue perfusion, physiological state, age, health conditions, interacting substances, dosing conditions, and other determinants of systemic exposure. BMI can provide context for body-composition differences, while age and health conditions can influence circulation, tissue distribution, hepatic handling, or gastrointestinal processes. Drug interactions can change metabolic clearance and thereby alter how much parent sildenafil remains available for redistribution. Food and gastric emptying can change the timing of systemic input before distribution begins. Alcohol and smoking can modify physiological or metabolic conditions that interact with exposure. These factors should not be treated as automatic causes of longer or shorter duration. Instead, they can modify one or more parameters of the compartmental system. Distribution-driven duration is an integrated outcome in which tissue uptake, redistribution, plasma exposure, metabolism, and pharmacodynamic response combine to determine how long relevant exposure persists.
Timing consistency describes how reproducibly distribution-related PK and PD events occur under comparable conditions. Relevant events can include the timing of peak plasma concentration, the initial distribution phase, the rate of plasma decline, redistribution, and the eventual reduction of effect. Consistency depends on the stability of absorption, systemic exposure, tissue distribution, metabolic clearance, and pharmacodynamic response. If these variables remain similar, similar compartmental trajectories may recur. If food, interacting substances, physiological state, dosing conditions, or metabolic activity change, the distribution profile may also change because the amount and timing of systemic drug entering tissues are different. Timing consistency therefore describes repeatability within a defined context rather than a universal distribution pattern. A reproducible distribution profile can still differ substantially between individuals. The important distinction is between stable timing within a given physiological setting and the broader biological variability that can produce different exposure-persistence patterns.